Ambrose Kristen 4

What Happened
Kristen Ambrose, SVP & Chief Accounting Officer at Vertex Pharmaceuticals (VRTX), disposed of a total of 1,968 shares in two transactions in February 2026, generating roughly $910,851 in proceeds. On 2026-02-10, 592 shares were surrendered/withheld at $468.41 per share (≈ $277,299) to satisfy tax or exercise obligations. On 2026-02-11, she sold 1,376 shares in an open-market transaction at $460.43 per share (≈ $633,552). Both actions are sales (not purchases) and are commonly routine (tax withholding and an open-market sale).

Key Details

• Transaction dates & amounts:
  • 2026-02-10 — 592 shares withheld/surrendered at $468.41 each; proceeds/consideration ≈ $277,299 (code F: tax/exercise withholding).
  • 2026-02-11 — 1,376 shares sold open market at $460.43 each; proceeds ≈ $633,552 (code S: sale).
• Combined proceeds ≈ $910,851.
• Footnote: Transactions were made pursuant to a company-approved Rule 10b5-1 trading plan entered 08/08/2025.
• Shares owned after the transactions: not specified in the information provided.
• Filing timeliness: Form 4 was filed on 2026-02-12 for transactions on 02-10 and 02-11 — appears timely (not marked late).

Context
The 02-10 “F” entry reflects shares surrendered or withheld to cover tax obligations from a prior equity award or option exercise (a withholding, not a market purchase). The 02-11 “S” entry is a straightforward open-market sale. Sales and tax-withholding transactions are common for executives and don’t necessarily signal a change in view about the company; they are routine liquidity or tax-management events. The presence of a 10b5-1 plan indicates at least some transactions were pre-scheduled under an approved trading plan.